Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients
Abstract
Andri Rezano, Afifa Khairinnisa, Savira Ekawardhani.
Depression and diabetes are diseases that share similar mechanisms with the aging process, specifically inflammation and oxidative stress. Metformin is an approved drug to treat diabetes but appears to several aging-related mechanisms. It currently targets multiple pathways of aging that involves the AMPK pathway, mTOR pathway, and IGF-1 signaling pathway. Thus, for its aging-related mechanism, glucose metabolism may not be the most important one. This study reviews 12 types of research related to the use of metformin to treat depression. This study used online research engines such as PubMed and Google Scholar to review the current finding of metformin and depression-related issues. We found that metformin targets age-related diseases, such as neurocognitive functions other than to regulate blood glucose levels through multiple biological pathways. And the final result of how metformin can be deployed against the aging process might help other researchers and clinicians to determine how to best use this drug.
| How to Cite this Article |
| Pubmed Style Rezano A, Khairinnisa A, Ekawardhani S. Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients. SRP. 2020; 11(7): 232-239. doi:10.31838/srp.2020.7.37 Web Style Rezano A, Khairinnisa A, Ekawardhani S. Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients. http://www.sysrevpharm.org/?mno=127181 [Access: March 30, 2021]. doi:10.31838/srp.2020.7.37 AMA (American Medical Association) Style Rezano A, Khairinnisa A, Ekawardhani S. Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients. SRP. 2020; 11(7): 232-239. doi:10.31838/srp.2020.7.37 Vancouver/ICMJE Style Rezano A, Khairinnisa A, Ekawardhani S. Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients. SRP. (2020), [cited March 30, 2021]; 11(7): 232-239. doi:10.31838/srp.2020.7.37 Harvard Style Rezano, A., Khairinnisa, . A. & Ekawardhani, . S. (2020) Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients. SRP, 11 (7), 232-239. doi:10.31838/srp.2020.7.37 Turabian Style Rezano, Andri, Afifa Khairinnisa, and Savira Ekawardhani. 2020. Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients. Systematic Reviews in Pharmacy, 11 (7), 232-239. doi:10.31838/srp.2020.7.37 Chicago Style Rezano, Andri, Afifa Khairinnisa, and Savira Ekawardhani. "Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients." Systematic Reviews in Pharmacy 11 (2020), 232-239. doi:10.31838/srp.2020.7.37 MLA (The Modern Language Association) Style Rezano, Andri, Afifa Khairinnisa, and Savira Ekawardhani. "Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients." Systematic Reviews in Pharmacy 11.7 (2020), 232-239. Print. doi:10.31838/srp.2020.7.37 APA (American Psychological Association) Style Rezano, A., Khairinnisa, . A. & Ekawardhani, . S. (2020) Metformin as an Antidepressant in Type 2 Diabetes Mellitus Patients. Systematic Reviews in Pharmacy, 11 (7), 232-239. doi:10.31838/srp.2020.7.37 |
Abstract
PDF
How to cite this article
Related Records